
Compare EAU and AUA testosterone cutoffs and learn how symptoms, repeat testing, assay quality and SHBG shape clinical interpretation.

The European Association of Urology (EAU) and American Urological Association (AUA) set different testosterone cutoffs for deciding when low results support a diagnosis of testosterone deficiency.
This article is for informational purposes and is not medical advice. Personal testing and treatment decisions belong with a qualified clinician.
The EAU addresses late-onset hypogonadism through a combined clinical and laboratory assessment. Its guideline requires compatible symptoms or signs alongside low morning total testosterone confirmed on at least two occasions using a reliable assay.
The EAU recommends 12 nmol/L (3.5 ng/mL) as a diagnostic threshold when the clinical picture is compatible. It also recommends repeating results below that level on separate occasions before treatment. The threshold therefore sits within an assessment rather than replacing it.
The EAU identifies reduced libido, erectile dysfunction and fewer spontaneous or morning erections as more specific symptoms than several physical or psychological complaints. These symptoms help shape the assessment. None establishes the diagnosis by itself.
This distinction matters because symptoms associated with hypogonadism are not exclusive to it. A clinician needs to understand the reported problem alongside the biochemical findings. The question is whether those findings fit together, not simply whether a symptom appears on a list.
The EAU also says symptom questionnaires have poor specificity and should not be used for systematic screening. In plain language, a questionnaire can identify complaints without reliably establishing their cause. A symptom score should not be treated as a substitute for clinical evaluation.
Epic Research's summary of the AUA guideline describes total testosterone below 300 ng/dL as a reasonable cutoff. The summary pairs that cutoff with compatible symptoms or signs and two early-morning measurements.
The numerical decision point differs from the EAU threshold. The shared feature is the need to connect laboratory evidence with clinical findings. Neither approach describes diagnosis as simply choosing a number from a report.
There is also an important distinction in scope. The EAU recommendation discussed here concerns late-onset hypogonadism. Epic Research describes the AUA recommendation as a cutoff for testosterone deficiency. Keeping those contexts visible is more useful than treating the figures as competing definitions of health for every man.
For someone reading a result, the practical question is which guideline framework the clinician is applying and why it fits the assessment. Selecting whichever cutoff gives the preferred answer would leave the clinical question unresolved.
The thresholds should not be presented as interchangeable universal normal ranges. They come from different guideline approaches and must be interpreted within their clinical context. A diagnostic cutoff is a decision aid, not a complete description of hormonal health.
This is where the comparison moves beyond the figures. Clinicians also weigh test conditions and measurement quality. They consider whether protein binding or another health issue changes the meaning of the result. Our guide to putting a testosterone result in clinical context explains that broader reading of laboratory reports.
The EAU recommends fasting morning testing, generally between 07:00 and 10:00. These conditions are part of its diagnostic approach rather than optional details attached to the cutoff.
The guideline reports that non-fasting testing can underestimate total testosterone by more than 30% in some circumstances. That finding does not mean eating produces the same change in every man. It explains why sampling conditions deserve attention when interpreting a low result.
For night-shift workers, the EAU says sampling should follow adequate sleep because the daily rhythm is linked to sleep patterns. A clock time alone does not capture that situation. The sleep schedule belongs in the discussion with the clinician arranging the assessment.
The useful distinction is between a concentration measured under documented conditions and a number read without that background. Before attaching meaning to the cutoff, the clinical team needs to know how the sample was obtained.
Repeat testing addresses a separate issue: whether the initial result represents a man's usual testosterone level. The EAU recommends confirmation on separate occasions rather than inferring persistent deficiency from one measurement.
A repeat test is therefore not merely an administrative requirement before treatment. It supplies another piece of evidence about the laboratory finding. The interpretation then depends on the pattern of results alongside the clinical assessment.
Our explanation of why clinicians confirm an initial low result gives more context for that step. For a consultation, it is useful to distinguish an initial finding from a confirmed pattern instead of describing both as an established diagnosis.
An assay is the laboratory method used to measure a substance. The EAU identifies LC-MS/MS as the most accurate method for sex-steroid evaluation. It also says standardized automated immunoassays can correlate well with that method.
That distinction does not support dismissing every automated testosterone test. It supports asking whether the laboratory method is reliable and appropriately standardized. The EAU also emphasizes collaboration with laboratories when interpreting results.
Free testosterone requires a separate method discussion. The EAU advises against direct immunoassay estimates because they are not accurate. It identifies equilibrium dialysis as the most accurate measurement method and allows calculation using SHBG and albumin as an alternative.
A report labelled “free testosterone” therefore needs method context. The name of the test alone does not establish how the value was obtained. Comparing results without understanding the methods can leave an important part of the assessment unexamined.
Total testosterone can be affected by sex hormone-binding globulin, usually shortened to SHBG. The EAU recommends considering SHBG measurement and free-testosterone calculation when relevant conditions affect protein binding.
The guideline lists obesity and insulin resistance among factors associated with lower SHBG. It lists aging and hyperthyroidism among factors associated with higher SHBG. These associations help explain why the same total testosterone result may require different interpretation in different clinical settings.
The EAU specifically notes the value of assessing free testosterone in some older men with obesity and in other circumstances affecting SHBG. This is not a recommendation to replace total testosterone with free testosterone in every assessment. It is a reason to consider whether total testosterone provides enough context for the case being evaluated.
The important comparison is therefore not just EAU versus AUA. It is also the numerical threshold versus the biological setting in which that number was measured. Our discussion of when SHBG makes free testosterone relevant develops that distinction.
The EAU advises clinicians to consider accompanying diseases and medications or substances that can interfere with testosterone production or action. These factors belong in the evaluation rather than being treated as background information unrelated to the laboratory result.
Acute disease is another specific consideration. The EAU associates it with functional hypogonadism and advises avoiding testosterone measurement in those circumstances. That recommendation separates assessment during an acute illness from evaluation of a man's usual hormonal state.
For personal decisions, a qualified clinician can determine how these circumstances affect the assessment. Neither a symptom checklist nor a preferred threshold can resolve that question on its own.
A reported Army finding illustrates why the distinction matters. The Hill reported in 2026 that 25.7% of active-duty male Army personnel in an Army-sponsored study had a morning testosterone result below 300 ng/dL.
The report also included a study author's caution that this finding alone was insufficient to diagnose hypogonadism. Diagnosis generally requires consistent symptoms or signs and repeatedly low concentrations. The percentage described a particular military study population and testing context, not the prevalence of diagnosed hypogonadism among adult men generally.
The lesson is about how the finding should be described. “A result below a cutoff” and “a diagnosed condition” are different outcomes. Keeping that distinction clear prevents a screening finding from becoming a broader claim than the evidence supports.
The guideline comparison can support a focused conversation rather than a debate over which number is universally correct. Useful questions include:
These questions follow the evidence without turning it into a self-diagnosis checklist. Their purpose is to clarify the assessment with a qualified clinician, not to select a treatment from a laboratory report.
View testosterone thresholds as part of a combined assessment of symptoms, repeated measurements and biological context rather than as isolated verdicts.
A guideline cutoff sets a decision point, and Testostra explains the biomarkers behind that decision without making it for the reader. Its evidence-led coverage of SHBG alongside total and free testosterone addresses confusion about laboratory results while keeping general education separate from an individual diagnosis or treatment plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra